Skip to main content
. Author manuscript; available in PMC: 2013 Jun 17.
Published in final edited form as: J Am Coll Surg. 2009 May;208(5):906–916. doi: 10.1016/j.jamcollsurg.2009.01.035

Table 6.

Univariate Analysis of Factors that Influenced the Use of Breast Conservation Surgery vs Mastectomy

Feature BCS Mastectomy p Value Relative risk* (95% CI)
Age (y), mean (SD) 66.7 (10.05) 66.6 (10.1) 0.97
Biomarker
  ER+/PR+ 34 35 0.82
  ER+/PR 14 13
Pre-AI cT stage
  cT2 36 16
  cT3/4 12 32 <0.0001 2.4 (1.5–3.7)
Clinical N stage
  cN0 31 29 0.67
  cN1/2 17 19
Histologic subtype
  Ductal 39 33
  Lobular 9 15 0.16
Pre-AI surgical status
  Marginal BCS 30 16
  Ineligible BCS 15 24 0.0042 1.84 (1.18–2.88)
  Inoperable 3 8
Clinical response
  PR + CR 35 26
  SD + PD 11 19 0.0632 1.49 (1.0–2.2)
Post-AI cT stage
  cT0/1 24 9
  cT2/3/4 24 39 0.0013 2.27 (1.26–4.1)
Pathologic T stage
  p < T2 47 32
  pT3,4 1 16 <0.0001 2.32 (1.73–3.11)
Pathologic N stage
  pN0 28 11
  pN1–3 20 37 0.0004 2.3 (1.35–3.9)
*

Relative risks and 95% CI of having a mastectomy were calculated with a feature’s lower level as reference.

Includes ductal with lobular features.

cT and cN indicates clinical T and N stage.

AI, aromatase inhibitor; BCS, breast-conserving surgery; CR, complete response; ER, estrogen receptor; PD, progressive disease; PR, progesterone receptor; SD, stable disease.